https://scholars.lib.ntu.edu.tw/handle/123456789/463787
Title: | Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel | Authors: | CJ Langer V Hirsh I Okamoto FANG-JU LIN Y Wan S Whiting T J Ong MF Renschler MF Botteman |
Keywords: | albumin-bound (nab) paclitaxel; solvent-based paclitaxel; non-small-cell lung cancer; quality-adjusted survival; Q-TWiST | Issue Date: | 2015 | Publisher: | NATURE PUBLISHING GROUP | Journal Volume: | 113 | Journal Issue: | 1 | Start page/Pages: | 20 | Source: | British journal of cancer | Abstract: | © 2015 Cancer Research UK. All rights reserved. This analysis compared the quality-adjusted survival and clinical outcomes of albumin-bound paclitaxel+carboplatin (nab-PC) vs solvent-based paclitaxel+carboplatin (sb-PC) as first-line therapy in advanced non-small-cell lung cancer (NSCLC) in older patients.Methods:Using age-based subgroup data from a randomised Phase-3 clinical trial, nab-PC and sb-PC were compared with respect to overall response rate (ORR), overall survival (OS), progression-free survival (PFS), quality of life (QoL), safety/toxicity, and quality-adjusted time without symptoms or toxicity (Q-TWiST) with ages ≥60 and ≥70 years as cut points.Results:Among patients aged ≥60 years (N=546), nab-PC (N=265) significantly increased ORR and prolonged OS, despite a non-significant improvement in PFS, vs sb-PC (N=281). Nab-PC improved QoL and was associated with less neuropathy, arthralgia, and myalgia but resulted in more anaemia and thrombocytopenia. Nab-PC yielded significant Q-TWiST benefits (11.1 vs 9.8 months; 95% CI of gain: 0.2-2.6), with a relative Q-TWiST gain of 10.8% (ranging from 6.4% to 15.1% in threshold analysis). In the ≥70 years age group, nab-PC showed similar, but non-significant, ORR, PFS, and Q-TWiST benefits and significantly improved OS and QoL.Conclusion:Nab-PC as first-line therapy in older patients with advanced NSCLC increased ORR, OS, and QoL and resulted in quality-adjusted survival gains compared with standard sb-PC. |
URI: | https://scholars.lib.ntu.edu.tw/handle/123456789/463787 | ISSN: | 0007-0920 1532-1827 |
DOI: | 38719989 10.1038/bjc.2015.181 |
Appears in Collections: | 臨床藥學研究所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.